The seroprevalence of hepatitis C virus (HCV) infection among Canadians is estimated at 0.3% to 0.9%. Of those with chronic HCV infection, 10% to 20% will experience advanced liver disease by 30 years of infection. Targeted screening seems a plausible strategy. We aimed to estimate the health and economic effects of various screening and treatment strategies for chronic HCV infection in Canada.
T he growing burden of chronic hepatitis C virus (HCV) infection poses a significant public health concern. A recent study of disease burden in Ontario ranked hepatitis C first among all infectious diseases. 1 Managing chronic HCV infection is difficult because the disease is clinically silent in most of those affected. Patients in whom the infection goes unrecognized and untreated may present with late-stage disease, which has potentially fatal complications. These complications may be reduced by offering timely treatment. 2 In the United States, recently revised screening recommendations suggest that those born between 1945 and 1965 should be screened. 3 It would be helpful to ascertain whether these US recommendations would be cost-effective in Canada, given differences in epidemiology of the disease and in health care systems between the 2 countries. 2 The issue of cost is particularly salient because several new, effective but expensive regimens for treating chronic HCV infection are in development. 4 The markedly improved tolerability of these new regimens and the anticipated high cure rates are likely to increase substantially both treatment uptake and overall treatment costs. However, higher efficacy may also lead to reduced downstream costs related to the complications of end-stage liver disease. The Public Health Agency of Canada is reviewing its hepatitis C screening guidance to determine whether expanded screening might reduce the number of undiagnosed infections. The objective of this study was to develop a model for projecting the health and economic effects of various 1-time screening strategies for chronic HCV infection for different populations within Canada.
Methods

Study cohort
We developed a state-transition model of HCV to assess the cost-effectiveness of alternative screening strategies for patients with chronic HCV mono-infection in Canada.
Cost-effectiveness of screening for hepatitis C in Canada
We included individuals living in Canada at the time of the 2011 population census. Our baseline analyses considered 1-time screening for individuals 25-64 years of age or 45-64 years of age.
Treatments considered
We assumed that patients with chronic HCV infection who are offered antiviral therapy would be treated with pegylated interferon (peginterferon) plus ribavirin, simeprevir-based combination therapy, sofosbuvir-based combin ation therapy or ABT-450-based interferon-free combination therapy, according to Canad ian guidelines or the results of phase 3 clinical trials. [5] [6] [7] [8] [9] [10] [11] [12] Peginterferon-ribavirin is currently funded by most drug plans in Canada. Simeprevir-based combination therapy has been approved by Health Canada and was recently recommended by the Canadian Agency for Drugs and Technologies in Health for treating genotype 1 infection. 13 Sofosbuvir-based combination therapy has also been approved by Health Canada and was recommended by the Canadian Agency for Drugs and Technologies in Health for treating genotypes 1, 2 and 3 infection.
14 ABT-450-based interferon-free combination therapy has recently completed phase 3 clinical trials 11 and has not yet been approved by Health Canada.
Screening strategies
We considered 4 screening strategies for the baseline cost-effectiveness analysis.
No screening (status quo): We assumed that 69.5% (50%-85% in sensitivity analysis) of HCV-infected patients are initially unaware of their infection and do not receive antiviral treatment. 15 We also assumed that each year 0.68% of these infected but unaware individuals discover their infection. 16 Among those whose infection remains undetected, we assumed that liver disease is detected upon development of cirrhosis with liver failure and/or hepatocellular carcinoma.
Screen and treat with peginterferon-ribavirin: Individuals are offered 1-time screening for HCV infection by their primary care phys ician at a visit scheduled for another purpose (a "case-finding" strategy). Screening involves a blood test for HCV antibody. All tests with a positive antibody result will be followed by a test for HCV RNA to confirm the infection. In our analysis, we assumed that all individuals with positive results for both tests are referred to a hepatologist, gastroenterologist or infectious disease specialist and may be offered treatment with peginterferon-ribavirin, according to current Canadian guidelines. 5 Screen and treat with peginterferon-ribavirinbased direct-acting antiviral agents: We used the same assumptions as outlined for the second strategy (screen and treat with peginterferonribavirin). Here, however, we assumed that patients with geno type 1 infection will be offered simeprevir-based combination therapy, 8, 9 patients with genotype 2 or 3 infection will be offered sofosbuvir-based combination therapy, 7, 12 and patients with any other genotypes will be offered peginterferon-ribavirin. 5 Screen and treat with interferon-free directacting antiviral agents: We used the same assumptions as outlined for the third strategy (see above), except we assumed that patients with genotype 1 infection will be offered interferon-free therapy (i.e., ABT-450-based interferon-free combination therapy).
10,11
Decision model
We developed a cohort-based, state-transition model using TreeAge Pro 2013 software. 17 In our simulations, cohort members moved between predefined health states in weekly cycles until all members had died. Health states are shown in Figure 1 and allowable transitions among health states in Appendix 1 (available at www.cmaj.ca /lookup/suppl/doi:10.1503/cmaj.140711/-/DC1).
Model parameters
We obtained model parameters (listed in Table 1  and Table 2 ), including disease progression parameters, probabilities of transition to advanced liver disease, mortality rates, treatment-related efficacy, epidemiologic variables and direct medical costs, from the literature [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (refer to Appendix 2, available at www.cmaj.ca/lookup /suppl/doi:10.1503/cmaj.140711/-/DC1 for detailed descriptions of these parameters). We obtained utility data for various health states from the most recent and valid Canadian utility study available, published by Hsu and colleagues 47 in 2012 and based on the Health Utilities Index Mark 2. That study included 700 patients across different chronic HCV infection health states.
Economic assumptions
We conducted our analysis from the payer's perspective and structured it as a cost-utility analysis, with outcomes expressed in terms of quality-adjusted life-years (QALYs) and costs. Future costs and health benefits were discounted at 5% annually.
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Results
Model validation
For validation purposes, we ran our model using the baseline parameter values. As shown in Appendix 3 (available at www.cmaj.ca/lookup /suppl/doi:10.1503/cmaj.140711/-/DC1), we compared the predicted outcomes of our model against data reported in other studies. 57, 60, 61 These outcomes included probability of progression to cirrhosis and probability of liver-related death. The results of our model closely matched the results of the other studies. 57, 60, 61 Base case In our baseline analysis for individuals 25-64 years old (Table 3) , the screen-and-treat strategies were more costly but also more effective than no screening. According to the baseline model, for every 10 000 people screened, about 63 HCV cases would be identified, and 37 (59%) of these patients would be eligible for treatment. Identifying these 37 cases and treating them would prevent 9 HCV-related deaths if peginterferon-ribavirin were used for treatment or 18 HCV-related deaths if direct-acting antiviral therapy were used over the lifetime of the cohort (Table 4) . As such, the number of individuals that would have to be screened to prevent 1 HCV-related death would be 1112 (10 000/9) if peginterferon-ribavirin were used for treatment or 556 (10 000/18) if direct-acting antiviral therapy were used for treatment.
In the model, when peginterferon-ribavirin was used for treatment, the screen-and-treat strategy increased life expectancy for the whole population (by 0.0119 life-years) and especially for patients with chronic HCV infection (by 2.06 life-years). The health benefit was 0.0032 QALYs per person screened (1.2 qualityadjusted days). Screening increased HCV-related costs by $124 per person, which resulted in an incremental cost-effectiveness ratio of $38 117 per QALY gained, relative to no screening (Table 3) .
Use of peginterferon-ribavirin-based directacting antiviral (i.e., simeprevir) for treatment increased life expectancy by 0.0202 life-years (Table 3) .
Use of interferon-free direct-acting antiviral (i.e., ABT-450-based combination therapy) for treatment, assuming a cost of $50 000 per treatment course, increased life expectancy by 0.0226 life-years for the entire baseline population or 4.18 life-years for those with chronic HCV infection. Compared with no screening, this Note: HCV = hepatitis C virus. *The study 47 did not include patients with decompensated cirrhosis, so utility for these patients was determined by adjusting the chronic HCV infection utility score according to a disutility value published in the systematic review. 48 approach resulted in a net cost increment of $266 and 0.0077 QALYs gained per person, which translated to an incremental cost-effectiveness ratio of $34 783 per QALY gained (Table 3) . We repeated the 4 screening strategies by considering 1-time screening for individuals 45-64 years of age. The results (Table 3) showed that it would also be cost-effective to screen and treat patients with chronic HCV infection in this age group, with incremental cost-effectiveness ratios of $34 359 per QALY for treatment with peginterferon-ribavirin, $35 562 per QALY for treatment with interferonfree direct-acting antiviral therapy and $44 034 per QALY for treatment with peginterferonribavirin-based direct-acting antiviral therapy, relative to no screening.
Scenario analyses
We conducted various scenario analyses to examine the cost-effectiveness of the screening program under different assumptions (where scenario analyses involve assumptions other than those used for the base-case analysis, usually with adjustments to multiple parameters simultaneously). In these scenario analyses, we repeated the 4 screening strategies with different age ranges (Appendix 4, available at www.cmaj.ca /lookup /suppl/doi:10.1503/cmaj.140711/-/DC1), different treatment patterns (Appendix 5, available at www.cmaj.ca/lookup/suppl/doi:10.1503 /cmaj .140711 /-/DC1) and restricted treatment (Appendix 6, available at www.cmaj.ca/lookup /suppl/doi:10 .1503/cmaj.140711/-/DC1).
In our baseline analysis, we assumed that the probability of being treated anywhere in Canada was similar to that at a single tertiary care hospital (Toronto Centre for Liver Disease, Toronto Western Hospital, University Health Network, Toronto, Ontario). Under this assumption, the incremental cost-effectiveness ratio for treatment with interferon-free direct-acting antiviral therapy was $34 783 per QALY, compared with no screening. To estimate future treatment patterns for patients with chronic HCV infection, we surveyed physicians treating such patients in Ontario Note: ∆ = change; DAA = direct-acting antiviral agent; G1 = genotype 1; G2/3 = genotype 2 or 3; G4/5/6 = genotype 4, 5 or 6; ICER = incremental cost-effectiveness ratio; PEG IFN+RBV = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SOF+RBV = sofosbuvir plus ribavirin. *Within each age group, options are ordered by exact cost; here, costs are presented to the nearest dollar. †Extended dominance, i.e., the combination of 2 other alternatives dominated the treatment. In cost-effectiveness analyses, extended dominance rules out any intervention that has an ICER greater than that of a more effective intervention.
for their treatment preferences among antiviral regimens expected to be available in Canada in the next 5 years. The survey results indicated that the treatment rate for treatment-naive patients would be 87.5%, provided interferonfree direct-acting antiviral was available (unpublished data). In this scenario analysis (Appendix 5), using a probability of treatment of 87.5% for patients with genotype 1, 2 or 3, the incremental cost-effectiveness ratio with interferon-free direct-acting antiviral treatment declined from $34 783 to $28 459 per QALY, compared with no screening.
The Canadian Agency for Drugs and Technologies in Health has recommended that treatment be limited to patients with fibrosis stages 2 to 4. 13 In this scenario analysis (Appendix 6), with treatment limited to patients with fibrosis stages 2 to 4, the incremental cost-effectiveness ratios increased as follows: from $38 117 to $47 466 per QALY for screening and treatment with peginterferon-ribavirin, from $42 398 to $47 573 per QALY for screening and treatment with peginterferon-ribavirin-based direct-acting antiviral therapy, and from $34 783 to $38 298 per QALY for screening and treatment with interferon-free direct-acting antiviral therapy.
Most of the scenario analyses indicated that it would be cost-effective to screen and treat patients with chronic HCV infection in the age range 25-64 years old or 45-64 years old.
Sensitivity analyses
We performed both 1-way deterministic sensitivity analyses and probabilistic sensitivity analyses, using the same assumptions as the base-case analysis, to explore the effect of uncertainty of the model's parameters.
For the deterministic sensitivity analyses, Appendix 7 (available at www.cmaj.ca/lookup /suppl /doi:10.1503/cmaj.140711/-/DC1) summarizes the effects of varying the parameters related to chronic HCV infection, to screening and to treatment, with use of tornado diagrams to examine the cost-effectiveness of screening.
Varying parameters related to chronic HCV infection, such as costs (excluding the cost of antiviral therapy) and utilities, had the largest Screen and treat with interferon-free DAA (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) 18 8 23 21
Note: DAA = direct-acting antiviral agent; G1 = genotype 1; G2/3: = genotype 2 or 3; G4/5/6 = genotype 4, 5 or 6; HCV = hepatitis virus C; PEG IFN+RBV = pegylated interferon plus ribavirin; SOF+RBV = sofosbuvir plus ribavirin. *According to the simulation, for every 10 000 people screened, about 63 cases of HCV would be identified. Of these cases, 37 (59%) would be eligible for treatment. Identifying these 37 cases by screening and treating them would prevent, over the lifetime of the cohort, 6 cases of decompensated cirrhosis, 3 cases of hepatocellular carcinoma and 9 HCV-related deaths if PEG IFN+RBV were used for treatment (relative to no screening) or 11 cases of decompensated cirrhosis, 8 cases of hepatocellular carcinoma and18 HCV-related deaths if DAAs were used for treatment (relative to no screening). †Values reported in the table have been rounded to whole numbers.
effect on the main results. The incremental costeffectiveness ratio generated from these sensitivity analyses for screening and treatment with peginterferon-ribavirin ranged from $18 264 to $39 780 per QALY. When we varied screening-related parameters, such as prevalence, screening acceptance rate, known HCV infection rate and cost of screening, the incremental cost-effectiveness ratio generated by screening and treatment with peginterferonribavirin ranged from $34 108 to $52 693 per QALY. In the sensitivity analysis on prevalence (see Appendix 8, available at www.cmaj .ca /lookup/suppl/doi:10.1503/cmaj.140711/-/DC1), the incremental cost-effectiveness ratio generated with screening and treatment with peginterferonribavirin remained under $50 000 as long as the prevalence was greater than 0.2%. For the parameter related to known HCV infection (see Appendix 7), the incremental cost-effectiveness ratio generated by screening and treatment remained under $50 000 for infection rates ranging from 15.7% to 50.7%. 15 According to our probabilistic sensitivity analyses, the chance that screening and treatment would cost less than $50 000 per QALY (relative to no screening) was 56% for peginterferonribavirin, 51% for peginterferon-ribavirinbased direct-acting antiviral therapy and 60% for interferon-free direct-acting antiviral therapy. The chance that screening and treatment would cost less than $100 000 per QALY was 71% for peginterferon-ribavirin, 76% for peginterferon-ribavirin-based direct-acting antiviral therapy and 77% for interferon-free direct-acting antiviral therapy (Appendix 9, available at www.cmaj.ca /lookup/suppl/doi:10 .1503/cmaj.140711/-/DC1).
Exploratory analysis
The price of interferon-free direct-acting antiviral therapy was unknown, so we conducted a threshold analysis to explore what the treatment costs would have to be for screening and treatment to be considered cost-effective under different willingness-to-pay thresholds (Appendix 10, available at www.cmaj.ca/lookup/suppl/doi :10.1503/cmaj.140711/-/DC1). We found that the incremental cost-effectiveness of screening and treatment with interferon-free direct-acting antivirals as first-line therapy would remain below $50 000 per QALY, relative to no screening, if a single course of therapy cost less than $112 145. At a willingness-to-pay threshold of $100 000 per QALY, screening and treatment with interferon-free direct-acting antivirals as first-line therapy would remain cost-effective if the cost of therapy was less than $310 262.
Interpretation
Our baseline analysis suggested that a selective, 1-time hepatitis C screening program in Canada for individuals aged 25-64 years or 45-64 years would prevent at least 9 HCV-related deaths per 10 000 persons over the lifetime of the cohort and is likely to be cost-effective, at $34 359 to $44 034 per QALY gained. The conventional upper limit of applied cost-effectiveness thresholds [50] [51] [52] varies among countries, from $50 000 to $120 000 per QALY. The results of multiple 1-way deterministic and probabilistic sensitivity analyses provided evidence that the screen-andtreat approach is likely to be cost-effective, taking into consideration the uncertainty of the model's parameters.
Published studies from the US have reported incremental cost-effectiveness ratios ranging from Can$18 800 to Can$90 000 per QALY for birth cohort screening and treatment with peginterferon-ribavirin or peginterferon-ribavirinbased direct-acting antiviral therapy. For ex ample, Rein and associates 50 reported an incremental cost-effectiveness ratio of US$15 429 per QALY for universal screening and treatment with peginterferon-ribavirin and US$31 100 per QALY for screening and treatment with telaprevir-based combination therapy. Eckman and colleagues 62 showed that it was cost-effective to screen for HCV and treat with boceprevir according to US guidelines (US$47 276 per QALY). Liu and associates 63 reported incremental costeffectiveness ratios of US$73 228 per QALY for universal birth cohort screening and treatment with peginterferon-ribavirin and US$59 835 per QALY for universal birth cohort screening and treatment with boceprevir. The authors of most of these studies concluded that it would be costeffective to offer 1-time screening for Americans born between 1945 and 1965. In part because of these findings, the US Centers for Disease Control and Prevention has, since August 2012, recommended 1-time testing for persons born from 1945 to 1965. 3 The Public Health Agency of Canada is now reviewing its screening guidance for HCV. Public health policy should be informed by consideration of health benefits, social and ethical values, feasibility and cost-effectiveness. Our analysis will assist in the development of HCV screening guidance by informing the last of these criteria. We believe that it offers scientifically valid projections based largely on Canadian data.
In Canada, the treatment uptake rate is low. In 2008, Sherman 64 estimated that only 20 000 to 30 000 HCV-infected individuals in Canada had been treated over the 15 years that treatment had been available. The adverse effects of peginter-feron-ribavirin therapy have been identified as a barrier to treatment uptake. 64, 65 The main adverse effects associated with peginterferon-ribavirin therapy are anemia, depression, rash, pruritus and flu-like symptoms. The peginterferon-ribavirinbased direct-acting antiviral simeprevir has substantially fewer of these adverse effects. 13 Phase 3 trials with interferon-free direct-acting antiviral therapy 10, 11, [66] [67] [68] [69] have shown high rates of sustained virologic response with no resistance or major adverse events in most populations. The interferon-free drugs are administered orally, and thus are tolerable, safe and convenient for patients. Uptake will likely increase when more interferon-free drugs become available. The results of our scenario analyses suggest that the screen-and-treat strategy is likely to remain costeffective if uptake is increased to 87.5%.
Limitations
Our analysis had some limitations. We may have overestimated adherence to therapy and underestimated the discontinuation rate relative to real clinical settings. In addition, the number of patients with cirrhosis in the trials was limited, which increases the uncertainty of treatment efficacy for this important population. Our analysis also assumed that the probability of being treated and the distribution of fibrosis stages for patients with chronic HCV infection in Canada were similar to those at a single tertiary care hospital (Toronto Western Hospital, University Health Network). In addition, similar to other published cohort simulation studies, 50, 62, 63 our analysis did not implicitly implement the time from diagnosis to treatment. Thus, the analyses cannot capture the full benefits or limitations for the time from diagnosis to treatment. We also did not consider every possible screening strategy. For example, we did not investigate the economic benefit of screening high-risk groups such as immigrants from high-burden countries, emergency department or in-hospital populations, skin-piercing practitioners or low-income groups. Recent studies in the US have shown that populations such as patients undergoing hemodialysis, 70 health care professionals, 71, 72 skin-piercing practition ers 73 and low-income groups 74 have contributed substantially to the overall prevalence of chronic HCV infection in that country. Screening for chronic HCV infection within these high-risk groups in Canada could be explored as an alternative strategy.
Conclusion
Our analyses suggest that in Canada, a 1-time program to screen for and treat HCV infection, aimed at birth cohort populations (25-64 or 45-64 years of age), is likely to be cost-effective. The screening programs that we evaluated would identify people with chronic HCV infection who are asymptomatic, which would in turn allow medical treatment to be offered, if needed, according to published guidelines, ideally before development of advanced liver disease. Early recognition of infected individuals and linkage of these people with care, treatment, alcohol and other lifestyle counselling, and other forms of support could reduce the large pool of undiagnosed HCV infections, save and prolong the lives of people with such infections, and avert the lengthy hospital stays and costs associated with HCV-related end-stage liver disease, liver transplant and hepatocellular carcinoma.
